

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

INT'L SERIAL NO.	PCT/EP2004/004245
INT'L FILING DATE	April 21, 2004
APPLICANT	BRUTON et al.
GROUP	1624
EXAMINER	Coleman
ATTORNEY DOCKET NO.	PB60227USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
/B.C./	1.	5,364,791	11/15/1994	Vegeto et al.			
/B.C./	2.	5,874,534	2/23/1999	Vegeto et al.			
/B.C./	3.	5,935,934	8/10/1999	Vegeto et al.			
/B.C./	4.	6,093,718	7/25/2000	Waterson et al.			
/B.C./	5.	2002/0115854	8/22/2002	Lam et al.			
/B.C./	6.	2003/0073718	4/17/2003	Barta et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
/B.C./	7.	WO96/10022	4/4/1996	PCT			
/B.C./	8.	WO97/06802	2/27/1997	PCT			
/B.C./	9.	WO97/23462	7/3/1997	PCT			
/B.C./	10.	WO02/32893	4/25/2002	PCT			
/B.C./	11.	WO02/47679	6/20/2002	PCT			
/B.C./	12.	WO02/072570	9/19/2002	PCT			
/B.C./	13.	WO02/076925	10/3/2002	PCT			
**/B.C./	14.	WO03/062234	7/31/2003	PCT			abstract
/B.C./	15.	WO03/004480	1/16/2003	PCT			
/B.C./	16.	WO03/024928	3/27/2003	PCT			
/B.C./	17.	WO03/024929	3/27/2003	PCT			
/B.C./	18.	WO03/088967	10/30/2003	PCT			
/B.C./	19.	WO03/103669	12/18/2003	PCT			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

/B.C./	20.	COTTET et al., Trifluoromethyl-Substituted Pyridines Through Displacement of Iodine by in situ Generated (Trifluoromethyl)copper, Eur. J. Org. Chem. 327-330 (2002).
/B.C./	21.	COTTET et al., Recommendable Routes to Trifluoromethyl-Substituted Pyridine- and Quinolincarboxylic Acids, Eur. J. Org. Chem. 1559-1568 (2003).
/B.C./	22.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavioral Brain Res. 104:147-155 (1999).
/B.C./	23.	GOODMAN et al., Desymmetrization of Dichloroazaheterocycles, Tetrahedron 55:15067-15070 (1999).
/B.C./	24.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TIPS 19:177-183 (May 1998).
/B.C./	25.	LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular Pharmacology 55:1101-1107 (1999).
/B.C./	26.	MICKELSON et al., Asymmetric Synthesis of 2,6-Methylated Piperazines, J. Org. Chem. 60:4177-4183 (1995).
/B.C./	27.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
/B.C./	27.	SAKAMOTO et al., Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1 Oxides with Trimethylsilylcarbonitrile, Chem. Pharm. Bull. 33(2):565-571 (1985).
/B.C./	29.	SCHLICKEER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).

Continue on page

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	10/27/2008
----------	------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\*\* Structures only